<DOC>
	<DOC>NCT02019030</DOC>
	<brief_summary>The purpose of this observational study is to evaluate the outcomes of using the PlasmaButton electrode in the treatment on Benign Prostatic Hyperplasia (BPH) while on anticoagulation medication.</brief_summary>
	<brief_title>Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Men with obstructive symptoms due to benign prostatic hyperplasia who are also on anticoagulant regimen. Anticoagulant regiments include: Aspirin 81mg, Aspirin 325mg, Adenosine diphosphate (ADP) receptor inhibitors, Cilostazol, Dabigatran, Dipyridamole, or Warfarin. The patient will be stable on their dosage regimen for at least 3 months. Maximum flow rate &lt;15ml/s by uroflowmetry. International Prostate Symptom Score (IPSS)â‰¥10. Patients with coagulopathy, INR exceeding 3. Anticoagulation dose changes within 3 months of surgery. Patients not medically cleared to undergo surgery for medical reasons. Patients with neurogenic bladder (bladder affected due to a neurologic cause). Urethral stricture, obstruction due to stricture. Suspected bladder or prostate cancer. Prostate size greater than 80 cc.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>benign prostatic hyperplasia</keyword>
	<keyword>Transurethral vaporization of prostate</keyword>
</DOC>